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Mutation analysis and clinical implications of von Willebrand Thrombotic microangiopathies (TMAs) encompass
factor–cleaving protease deficiency. mainly two syndromes: thrombotic thrombocytopenic
Background. The pentad of thrombocytopenia, hemolytic purpura (TTP) and the hemolytic uremic syndrome
anemia, mild renal dysfunction, neurologic signs, and fever, (HUS). TTP consists of microangiopathic hemolytic ane-classically characterizes the syndrome of thrombotic thrombo-
mia and thrombocytopenia associated with platelet ag-cytopenic purpura (TTP). TTP usually occurs in adults as an
gregation in the microcirculation responsible for isch-acquired form but a congenital form in children has also been
emic manifestations [1]. The pathophysiology of TTPdescribed. In the latter case, the initial presentation is often
with neonatal jaundice and thrombocytopenia. The disorder involves occlusion of small arterioles and capillaries by
may subsequently take a relapsing course. Deficiency of a re- platelet plugs containing high quantities of Von Wille-
cently identified novel metalloprotease, the von Willebrand brand factor (vWF) [2]. These platelet-rich microthrombi
factor (vWF)–cleaving protease, originating from mutations in are observed in the small vessels of various organs. vWF
the ADAMTS13 gene plays a major role in the development
is a large glycoprotein essential for platelet adhesion andof TTP.
aggregation, especially at the high shear stress–associatedMethods. Blood for DNA analysis was collected from six un-
hemodynamic conditions of the microcirculation [3]. vWFrelated TTP families, consisting of nine patients from four differ-
ent countries, and was screened for mutations in the ADAMTS 13 is synthesized as a large precursor protein that consists
gene. This gene spans 29 exons encompassing37 kb. Conven- of a 22 amino acid signal peptide, a propolypeptide of
tional techniques of DNA extraction, polymerase chain reac- 741 amino acids and a mature subunit of 2050 amino acids.
tion (PCR), and direct cycle sequencing were used. Dimers are formed in the endoplasmatic reticulum by
Results. Eight novel ADAMTS 13 mutations are presented.
covalent dimerization of the subunits at their C-termini.Half of the total number of mutant ADAMTS13 alleles are
Multimers are formed in the Golgi apparatus by covalentamino acid substitutions. The disease-causing mutations are
multimerization of the dimers at the D3 domain. vWFspread over the gene. The pathogenicity of the individual muta-
is released from endothelial cells as a series of multimerstions is based upon their predicted effect on the ADAMTS13
protein and segregation in family members. Although most of of very high molecular weight. The largest multimers of
the patients (seven out of nine) had symptoms during the vWF are the most biologically active. In the plasma, one
neonatal period, they were in a remarkably good condition. regulator of the size of the multimers is a specific metallo-
Only one of the nine patients had a decreased glomerular protease [4, 5], which cleaves the peptide bond between
filtration rate (GFR) with proteinuria and hematuria. Another
Y842-M843 of vWF mature subunit [6] and prevents thepatient had epileptic seizures.
interaction of the largest multimers with platelets. InConclusion. We confirm that deficiency of ADAMTS13 is
plasma of patients with TTP, unusually large multimersa molecular mechanism responsible for familial TTP. An early
diagnosis allows prophylactic treatment with fresh plasma infu- of vWF (UlvWF) have been observed [7].
sions. In 1998, a major breakthrough in the understanding
of TMA pathology occurred with the discovery of a defi-
cient activity of vWF-cleaving protease (either constitu-
Key words: TTP, ADAMTS 13, vWF-cleaving protease. tional or acquired via an autoantibody) specific for TTP
[8, 9]. In contrast, vWF-cleaving protease activity wasReceived for publication October 11, 2002
preserved in HUS [10]. Levy et al [11] recently identi-and in revised form December 19, 2002
Accepted for publication February 3, 2003 fied mutations in the of ADAMTS13 gene as the underly-
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Table 1. Clinical data of the thrombotic thrombocytopenic purpura (TTP) patients included in the study cohort
Patients 1 2a 3 4a 5 6a 7a 8a 9a
Gender Male Female Female Male Male Male Male Male Male
Age of diagnosis months 23 21 20 4 7 18 12 9 64
Start of prophylactic plasma 7 years 5 years, 3 years, Treatment 7 months, c7 years 2 years, Treatment c9 years
infusions 9 months 7 months symptom- cryopre- 6 months symptom-
atically cipitate atically
Other affected family members Possibleb  (brother)   (brother)   (brother)  (sister)  (brother)  (brother)
Consanguinity         
Symptoms in the neonatal period         
Jaundice         
Exchange-transfusions         
Thrombocytopenia     ?   ? 
Rhesus/ABO-incompatibility   ? ? ? ?  ? 
a Patient 2 and patient 7 are siblings, as well as patient 4 and patient 8 and patient 6 and patient 9, respectively
b Patient 1. Brother died immediately after birth. The autopsy revealed widespread thrombi, especially in the myocard, adrenal gland, kidney, and lungs
c Prophylactic treatment with hemate ( vWF/factor VIII concentrate) in these patients is described previously [25, 26]. These patients were treated with fresh-
frozen plasma before the treatment with hemate started.
ADAMTS13 is a newly identified member of the Mutation analysis
ADAMTS family of protein-cleaving proteinases. Cleav- Genomic DNA was extracted by a salting out proce-
age of endothelial cell derived ULvWF multimers by dure from peripheral blood lymphocytes [13]. Sequence
ADAMTS13 is a rapid physiologic process that occurs analysis was by polymerase chain reaction (PCR) and
on the endothelial cell surface. direct cycle sequencing. Cycle sequencing was carried out
In this article, we report the identification of eight by the Dye-deoxy Terminator method, using the ABI
ADAMTS13 mutations in a cohort of nine patients, in- Prism 377 sequencer (PE Applied Biosystems, Nieuwe-
cluding three affected sibling pairs from different geo- kerkaan de Ijssel, The Netherlands) following standard
graphical origins. The presumptive effects of these muta- procedures [14]. Primers were from Life Technologies
tions on the function of the ADAMTS13 protein are (Breda, The Netherlands). They were designed to permit
analyses of complete exons, including intron boundaries,discussed. We did not observe a hotspot for mutations
according to the public available sequence (AY 055376).in the ADAMTS13 gene. Finally, our findings suggest
The primer sequences and the PCR protocols are avail-genetic heterogeneity in familial TTP.
able upon request. To confirm the mutations, restriction
enzyme analysis with BsaJI (for exon 7 D235H), AlwNI
METHODS (for exon 7 6 bp deletion), RsaI (for exon 8), MboII (for
TTP families exon 9) and AluI (for exon 12) was performed according
to the manufacturer’s recommendation. The segregationOur study cohort consisted of nine children. All pa-
of mutations has been studied in members of the familytients were diagnosed as TTP. The clinical diagnosis of
of patients 1, 2, 3, 4, and 6.TTP was based on the presence of hemolytic anemia
with fragmented erythrocytes, and thrombocytopenia,
which could be accompanied by fever and decrease of RESULTS
GFR. All patients demonstrated a lack of vWF-cleaving Clinical and biochemical data
protease. The assay of vWF-cleaving protease activity
Clinical data were available for nine patients, con-was performed as described previously [12]. Briefly, di-
sisting of three sibling pairs and three cases with no
luted citrated plasma was activated by barium chloride. familial history of TTP. The diagnosis of TTP was made
This activated plasma was added to protease- free vWF. between the age of 4 and 64 months. Seven patients
The reaction was stopped by addition of ethylenedi- (including two affected sibling pairs) had symptoms of
aminetetraacetic acid (EDTA). The extent of vWF deg- jaundice or thrombocytopenia during the neonatal pe-
radation was assayed by multimer analysis using sodium riod, while three required neonatal exchange transfusion
dodecyl sulfate (SDS)-electrophoresis in 1.4% agarose (Table 1). These early symptoms are likely to represent
gels. Following electrophoresis, the proteins were elec- the first symptoms of TTP. In Table 2 the current situa-
trotransferred to nitrocellulose, and vWF was visualized tion of the children is described. Surprisingly only one
with peroxidase-conjugated rabbit antibodies against hu- of the patients had a decreased glomerular filtration rate
man vWF. Patients 1, 2, and 7 were tested for vWF- (GFR).
cleaving protease in our hospital. Patients 3, 6, and 9
Mutation detection in the ADAMTS13 genewere tested by M. Furlan [4] with the same technique.
Patients 4, 5, and 8 were tested for the deficiency at the Human genomic DNAs from six TTP families, includ-
ing nine patients (three affected sibling pairs), have beenhospital of origin.
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Table 2. Current situation of the thrombotic thrombocytopenic purpura (TTP) patients
Patients 1 2a 3 4a 5 6a 7a 8a 9a
Current situation
Age years 11.5 15.5 18 4.5 17 13 11.5 7 15
Renal function
Glomerular filtration rate mL/min/1.73 m2 60 148 108 138 107 97 131 133 135
Proteinuria 0.4 g/L — — — — — — — —
Hematuria Microscopic — — — — — — — —
Hypertension — — — — — — — — —
Neurological symptoms — — Epileptic seizures — — — — — —
Other (ischemic) symptoms — — — Right Legg- — —
Calves-Perthes
a Patient 2 and patient 7 are siblings, as well as patient 4 and 8 and patient 6 and 9, respectively
Fig. 1. ADAMTS 13 mutations in two patients.
A deletion in exon 19 (A) of patient 5 and
the wild-type of exon 19 (B) are shown on
top. The mutation found in exon 8 of patient
1 (C ) and the wild-type exon 8 (D ) are shown
on the bottom.
screened for mutations in the ADAMTS13 gene by PCR mutation in the other allele of patient 4 (and patient 8)
predicts a truncated ADAMTS 13 protein. The homozy-in combination with DNA sequencing of 29 exons that
encode the complete coding region. A total of eight gous deletion in patient 5 and the homozygous insertion
in patient 6 (and patient 9) result in a frameshift and adifferent mutations have been identified consisting of
four missense mutations, two deletions, one insertion, and premature stop codon. The remaining four mutations all
result in nonconservative amino acid substitutions andone nonsense mutation (Fig. 1 and Table 3). All mutations
are novel molecular variants of the ADAMTS13 gene. In all occur at positions that are perfectly conserved be-
tween the human and mouse genes. The parents of theaddition, the mutations are spread over the gene (Fig. 2).
In our total study group of six unrelated families, four patients in families 1, 2, 3, 4, and 6 were all heterozygous
carriers of one mutant ADAMTS13 allele. All TTP pa-carry homozygous ADAMTS13 mutations (patients 1, 2,
5, and 6) and two are compound heterozygotes (patients 3 tients displayed homozygous or compound heterozygous
mutations in the ADAMTS13 gene. In addition, in alland 4). During the mutational analyses in the ADAMTS13
gene, 10 polymorphisms were observed. These appeared patients with homozygous or compound heterozygous
mutations clinical symptoms were evident. Heterozygousto be present in control alleles with variable frequency
and have previously been described at NCBI (http:// carriers were without symptoms. Fifty control chromo-
somes (one hundred alleles) were tested for the presencewww.ncbi.nlm.nih.gov).
The six base pair deletion observed in one allele of of the four missense mutations that have been identified
in our study group. All appeared to be absent in thesepatient 4 (and patient 8) caused the removal of two highly
conserved amino acids of the ADAMTS 13 protein. The control chromosomes.
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Table 3. ADAMTS13 mutations identified in thrombotic thrombocytopenic purpura (TTP) patients
Patient Exon Mutation at nucleotide Homo-heterozygous Predicted effect on protein
1 8 932G→A Homozygous C311Y
2  7 7 703G→C Homozygous D235H
3 9 1058C→T Heterozygous P353L
12 1370C→T Heterozygous P457L
4  8 7 718-724 Heterozygous Del G  C
21 2728C→T Heterozygous R910Stop
5 19 2279delG Homozygous Frameshift stop AA776
6  9 29 4143-4144InsA Homozygous Frameshift stop AA1386
function. The follow-up of our patients is reassuring,
even when no prophylactic plasma infusions were given.
This is certainly an unexpected finding. Only one patient
had a decrease of GFR with proteinuria and microscopicFig. 2. Mutations identified in the ADAMTS13 gene. Mutations of the
haematuria. One patient showed epileptic seizures andpresent communication are depicted above the corresponding exons.
Mutations previously described in literature are displayed below the corre- one Legg-Calves-Perthes of the right hip. Legg-Calves-
sponding exons. Symbols are: () missense mutations; () deletions/ Perthes disease can be the consequence of thromboticinsertions and splice-site mutations; () nonsense mutations.
events [19].
Among the ADAMTS13 mutations identified in our
DISCUSSION TTP cohort, three are likely to have a deleterious effect
on the function of ADAMTS13. The nucleotide deletionThe hypothesis that vWF-cleaving protease deficiency
(patient 5), the nonsense mutation (patients 4 and 8) andis central to the pathogenesis of familial TTP has recently
the insertion (patients 6 and 9) will cause premature termi-been supported by the identification of several mutations
nation of translation and result in truncated ADAMTS13in the ADAMTS13 gene in patients with familial TTP
proteins. Half of the mutations detected in our familial[11, 15]. In the present study, the specific involvement
TTP cohort, however, are amino acid substitutions. Ourof this protease in the etiology of this disorder is further
data together with the results of previous studies [11, 15]substantiated by the finding of eight novel mutations in
indicate that 15 out of a total of 23 identified mutanta cohort of six unrelated TTP families from different
ADAMTS13 alleles are missense mutations. These muta-geographic origins.
tions are inferred to be pathogenic when they substituteClinical data of the six patients and three affected
highly conserved amino acids, which in view of theirsiblings revealed important information. The diagnosis
conservation through evolution are presumed to be ofof TTP was made between 4 and 64 months of age. Seven
functional importance. All four missense mutations de-had, however, already symptoms in the neonatal period.
tected in our TTP cohort are substitutions of stronglyInterpretation of clinical data in patient 1 is complicated
conserved into nonconservative amino acids and wereby an associated streptococcal septicemia during the neo-
not found in 50 control chromosomes. Therefore, it isnatal period. In the neonate vWF-cleaving protease level
likely that the majority of these missense mutations areis decreased (average 52%; range, 25% to 118%) [16],
indeed harmful mutations and not innocuous polymor-but still in the range allowing cleavage of the large
phisms. However, to prove that these amino acid substi-multimers of vWF [10]. UlvWF multimers are present
tutions can indeed result in impairment or loss of functionin the majority of the plasma of the fetus and full-term
will require study of the effect of individual mutationsand preterm neonates. These UlvWF multimers disap-
on vWF cleavage in a functional expression system [15].pear within a few weeks after birth [17]. UlvWF multimers,
By expression analysis in HeLa cells Kokame et al [15]which are under normal circumstances not present in
could demonstrate that vWF-cleaving protease con-children and adults, contribute to platelet aggregation
taining two specified mutations were not secreted fromand hemostasis in the normal fetus and neonate. Plasma
cells, while in the case of two other mutations, mutantsvWF in neonates is more multimerized than in adults
were normally secreted but showed minimal activity.and this explains the increased platelet deposition on
These findings suggest that the clinical symptoms of thesubendothelium under flow conditions [18]. The possibil-
patients will be heterogeneous.ity exists that in patients with a congenital form of TTP,
The eight mutations detected in our study were pres-there are even more UlvWF multimers in the fetal and
ent in TTP patients from different geographic regions.neonatal phase than in normal fetuses and neonates.
This indicates that a common ancestor is unlikely.Possibly these UlvWF multimers cause thrombi and are
Of note, we were unable to identify a mutant allelethus responsible for the first signs of TTP. The manifesta-
in another patient, despite documented vWF-cleavingtion of TTP in our patients after a certain honeymoon
period suggests a physiologic maturation of the platelet protease deficiency. This patient has a typical history of
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6. Dent JA, Berkowitz SD, Ware J, et al: Identification of a cleavagecongenital TTP, presenting at birth with jaundice and
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has required prophylactic infusions with fresh-frozen malities in type IIA von Willebrand factor. Proc Natl Acad Sci
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ing fragments such as promoter or enhancer segments, the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584,
1998intron sequences or 5 and 3 noncoding regions, which
9. Tsai HM, Lian EC: Antibodies to von Willebrand factor–cleavinghave not yet been screened for mutations. Second, large
protease in acute thrombotic thrombocytopenic purpura. N Engl
heterozygous ADAMTS13 gene deletions will not be J Med 339:1585–1594, 1998
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11. Levy GG, Nichols WC, Lian EC, et al: Mutations in a memberbut still undetected cause for TTP in children [21].
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purpura. Nature 413:488–494, 2001
ADAMTS13 gene have been identified in a high percent- 12. Loo T: Levtchenko E, Furlan M, et al: Autosomal recessive inheri-
tance of von Willebrand factor–cleaving protease deficiency. Pedi-age of familial TTP patients studied to date, we conclude
atr Nephrol 14:762–765, 2000that the analysis of the ADAMTS13 gene may be re-
13. Miller SA, Dykes DD, Polesky HF: A simple salting out proce-
garded as a powerful diagnostic aid. Accurate diagnosis dure for extracting DNA from human nucleated cells. Nucleic
Acids Res 16:1215, 1988of congenital TTP is important as symptomatic episodes
14. Lemmink HH, Knoers NV, Karolyi L, et al: Novel mutations incan be prevented by periodic plasma transfusions. The
the thiazide-sensitive NaCl cotransporter gene in patients with
use of humanized monoclonal antibodies against the ex- Gitelman syndrome with predominant localization to the C-termi-
nal domain. Kidney Int 54:720–730, 1998tracellular domain of glycoprotein 1b (GP1b) modulat-
15. Kokame K, Matsumoto M, Soejima K, et al: Mutations and com-ing von Willebrand–mediated platelet adherence could
mon polymorphisms in ADAMTS13 gene responsible for von Wil-
offer another preferred form of treatment [22–24]. Re- lebrand factor–cleaving protease activity. Proc Natl Acad Sci USA
99:11902–11907, 2002peated fresh plasma infusions are accompanied by risk of
16. Mannucci PM, Canciani MT, Forza I, et al: Changes in healthallergic reactions and transmission of undetected viruses.
and disease of the metalloprotease that cleaves von Willebrand
factor. Blood 98:2730–2735, 2001
17. Katz JA, Moake JL, McPherson PD, et al: Relationship betweenACKNOWLEDGMENTS
human development and disappearance of unusually large von
We would like to thank Professor S.J. Machin, Department of Willebrand factor multimers from plasma. Blood 73:1851–1858,
Haematology, University College London, London; Dr. R. Liesner, 1989
Great Ormond Street Hospital, London; Dr. M. Williams, Birmingham 18. Shenkman B, Linder N, Savion N, et al: Increased neonatal platelet
Children’s Hospital, Birmingham, England, for their help in providing deposition on subendothelium under flow conditions: The role of
patient DNA; and Professor L. Holmberg, Department of Pediatrics, plasma von Willebrand factor. Pediatr Res 45:270–275, 1999
University of Lund, Lund, Sweden, for mutation analysis of two Swed- 19. Eldridge J, Dilley A, Austin H, et al: The role of protein C,
ish patients. We would also like to thank Dr. M. Te Loo, T. van der protein S, and resistance to activated protein C in Legg-Perthes
Velden, and Dr. E. Levtchenko, University Medical Centre, Nijmegen disease. Pediatrics 107:1329–1334, 2001
for their help in performing this study. 20. Robson WL, Tsai HM: Thrombotic thrombocytopenic purpura
attributable to von Willebrand factor–cleaving protease inhibitor
Reprint requests to Lambertus van den Heuvel, Ph.D., Department in an 8-year-old boy. Pediatrics 109:322–325, 2002
of Pediatric Nephrology, University Medical Centre Nijmegen, P.O. 21. Xie L, Chesterman CN, Hogg PJ: Control of von Willebrand
Box 9101, 6500 HB, Nijmegen, The Netherlands. factor multimer size by thrombospondin-1. J Exp Med 193:1341–
E-mail: B.vandenHeuvel@cukz.umcn.nl 1349, 2001
22. Perrault C, Moog S, Rubinstein E, et al: A novel monoclonal
antibody against the extracellular domain of GPIbbeta modulatesREFERENCES
vWF mediated platelet adhesion. Thromb Haemost 86:1238–1248,
20011. Ruggenenti P, Remuzzi G: Pathophysiology and management of
thrombotic microangiopathies. J Nephrol 11:300–310, 1998 23. Kageyama S, Matsushita J, Yamamoto H: Effect of a humanized
monoclonal antibody to von Willebrand factor in a canine model2. Asada Y, Sumiyoshi A, Hayashi T, et al: Immunohistochemistry
of vascular lesion in thrombotic thrombocytopenic purpura, with of coronary arterial thrombosis. Eur J Pharmacol 443:143–149, 2002
24. Ajzenberg N, Denis CV, Veyradier A, et al: Complete defect inspecial reference to factor VIII related antigen. Thromb Res 38:
469–479, 1985 vWF-cleaving protease activity associated with increased shear-
induced platelet aggregation in thrombotic microangiopathy.3. Ruggeri ZM: Structure and function of von Willebrand factor.
Thromb Haemost 82:576–584, 1999 Thromb Haemos 87:808–811, 2002
25. Karpman D, Holmberg L, Jirgard L, Lethagen S: Increased plate-4. Furlan M, Robles R, Lammle B: Partial purification and charac-
terization of a protease from human plasma cleaving von Wille- let retention in familial recurrent thrombotic thrombocytopenic
purpura. Kidney Int 49:190–199, 1996brand factor to fragments produced by in vivo proteolysis. Blood
87:4223–4234, 1996 26. Karpman D, Lethagen S, Kristoffersson A, et al: von Willebrand
factor mediates increased platelet retention in recurrent throm-5. Tsai HM: Physiologic cleavage of von Willebrand factor by a
plasma protease is dependent on its conformation and requires botic thrombocytopenic purpura. Thromb Haemost 78:1456–1462,
1997calcium ion. Blood 87:4235–4244, 1996
